Human papillomavirus (HPV) causes an estimated 830,000 new cancer cases and more than 400,000 deaths worldwide each year, yet the majority of these cancers are either 90 to 100% preventable through vaccination or detectable at an early stage through screening. The tools to eliminate this global health crisis already exist. What's missing is equitable access across high-, middle-, and low-income countries .

The World Health Organization has set an ambitious goal: eradicate cervical cancer by 2030. But without meaningful change in current practice, the projections are sobering. HPV-related cancers are projected to decrease by roughly 4% in Europe by 2045, while increasing by 105% in Africa over the same period . This disparity reflects a stark reality: 77% of HPV cancers occur in low- and middle-income countries, driven directly by limited access to vaccination and screening programs.

How Does HPV Lead to Cancer?

Nearly all of us will be exposed to HPV at some point, most commonly in our teens, twenties, or early thirties. For the vast majority, the immune system clears the infection within 18 to 36 months with no lasting harm. But in a subset of individuals, the virus integrates into host cells and produces proteins that disable two critical tumor suppressor genes, P53 and RB1. With those protective mechanisms knocked out, cells can grow without regulation, progressing from pre-invasive lesions to invasive cancer .

This mechanism underlies all HPV-related cancers. HPV accounts for over 90% of cervical cancer cases, likely closer to 100%, as well as significant proportions of anal, vaginal, vulvar, penile, and oropharyngeal cancers. Notably, oropharyngeal (head and neck) HPV cancers are rising rapidly, particularly among men. In the United States, they now surpass cervical cancer in incidence, accounting for approximately 20 to 40% of oral and pharyngeal cancers .

What Are the Global Disparities in HPV Cancer Burden?

The global distribution of HPV-related cancers mirrors patterns seen with other infection-driven malignancies. High-burden areas include Africa and Oceania, which have the highest incidence and death rates. Asia, due to its sheer population size, accounts for 58% of all HPV-related cancers globally .

The age-adjusted figures reveal the stark inequality:

• Highest-burden regions: 77 cases per 100,000 people, with 52 deaths per 100,000
• North America: 20 cases per 100,000 people, with 6 deaths per 100,000
• Lowest-burden regions (Middle East): 5 cases per 100,000 people, with 1 death per 100,000

Gender disparities compound the picture. An estimated 736,000 women develop HPV-related cancers annually compared to approximately 95,000 men, and nearly 400,000 women die of HPV-related cancers each year versus 44,000 men. This disparity is driven overwhelmingly by cervical cancer mortality in low-income settings .

How Do Screening Tests Detect HPV-Related Cancers?

Cervical cancer has the most mature and well-validated screening infrastructure of any HPV-related malignancy. Two primary screening modalities exist: the Pap smear and HPV testing .

The Pap smear, introduced in the United States in 1941, has been responsible for an approximately 86% decline in cervical cancer in high human development index countries. This is a remarkable achievement, particularly given that its sensitivity is only 50 to 80%, with a false-negative rate of 10 to 20%. Its success demonstrates what consistent population-level screening can accomplish even with an imperfect tool .

HPV testing, introduced in 1999 as an adjunct to Pap smears, offers substantially improved sensitivity of approximately 98%, with a specificity of 87% and a positive predictive value of 88%. The FDA approved it as a primary screening modality in 2014, and it has steadily become the preferred approach. Unlike Pap smears, HPV testing does not require a cytologist, significantly reducing cost and logistical complexity. In the U.S., an HPV test runs between $80 and $150 .

A transformative development came in 2024, when self-collected HPV testing received FDA approval. A 2025 meta-analysis found that self-collection with a mail-in option doubled screening rates among people who were not regularly screened, precisely the population at highest risk for cervical cancer. While the sensitivity for detecting cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is 74 to 86% and specificity is 80%, somewhat lower than clinician-collected samples, the dramatically higher participation rate more than compensates for this modest reduction. This approach holds particular promise for expanding equitable access in low- and middle-income countries, where clinic-based screening is limited .

How Effective Is HPV Vaccination at Preventing Cancer?

If screening is the net that catches HPV-related cancers early, vaccination is the wall that prevents them from occurring at all. The HPV vaccine story is one of the most compelling preventive oncology narratives of the past two decades .

The original Gardasil vaccine, targeting HPV strains 6, 11, 16, and 18, was approved for girls aged 9 to 26 in 2006 and for boys in 2009. Strains 16 and 18 are the two most oncogenic types, responsible for the majority of HPV-related cancers. In 2014, a nine-valent vaccine (HPV9) was approved, adding five additional oncogenic strains. By 2018, HPV9 was approved for men and women up to age 45. In 2019, over 100 countries had incorporated HPV vaccination into routine vaccination schedules, and in 2020 the FDA approved HPV9 specifically for the prevention of oropharyngeal cancers .

The vaccine's safety and efficacy record is exceptional. There has been no increase in serious adverse events compared to placebo, and immunogenicity is near-universal, with 99 to 100% seroconversion compared to only 50 to 70% from natural HPV infection. In HPV-naive individuals, the vaccine provides 91 to 100% protection against HPV 16 and 18, and 90% protection against CIN2 or greater. Even in individuals who have already had sexual debut and may have been previously exposed, efficacy remains meaningful: 76% against HPV 16 and 18, and 50% against CIN2 or greater .

The dosing schedule has also evolved to improve implementation. The original three-dose regimen proved challenging for many patients to complete. Non-inferiority studies demonstrated that two doses were equally effective in girls under 15, and more recently a trial of 20,000 girls aged 12 to 16 found one dose to be as efficacious as two, a finding with profound implications for global rollout and cost reduction .

Steps to Increase HPV Prevention and Screening Access

• Expand vaccination programs: Incorporate HPV9 into routine vaccination schedules in low- and middle-income countries, leveraging simplified dosing schedules (one or two doses) to reduce implementation barriers and costs
• Deploy self-collection screening: Scale mail-in HPV self-collection tests in underserved regions where clinic-based screening is limited, as this approach has doubled screening rates among previously unscreened populations
• Reduce screening costs: Work toward lowering the $80 to $150 cost of HPV testing in high-income settings and ensure affordable access in low-resource areas through subsidies or bulk procurement agreements
• Establish screening infrastructure: Build or strengthen cervical cancer screening programs in Africa and Oceania, regions with the highest incidence and death rates, to detect pre-invasive lesions before they progress to invasive cancer

"Without meaningful change in current practice, HPV-related cancers are projected to decrease by roughly 4% in Europe by 2045, while increasing by 105% in Africa over the same period," explained Dr. Barbara Goff, Professor and Chair of the Department of Obstetrics and Gynecology.

Dr. Barbara Goff, Professor and Chair of the Department of Obstetrics and Gynecology

The challenge ahead is not scientific but logistical and financial. The tools to prevent and detect HPV-related cancers exist and are proven effective. What remains is the commitment to equitable implementation across all income levels and regions. Without it, the burden of preventable cancer will continue to shift toward the world's poorest populations .